Department of Clinical Science, Intervention and Technology, Karolinska Institutet, Stockholm, Sweden.
Centre for Clinical Research Sörmland, Uppsala University, Uppsala, Sweden.
BMJ Open. 2022 May 27;12(5):e059877. doi: 10.1136/bmjopen-2021-059877.
The Swedish Pancreatitis Cohort (SwePan) was designed to study long-term outcomes following an episode of acute pancreatitis. It can also be used to study various risk factors for developing acute pancreatitis.
The SwePan is a register-based nationwide matched cohort. It includes all Swedish cases of acute pancreatitis during 1990-2019. It contains 95 632 individuals with acute pancreatitis and 952 783 pancreatitis-free individuals matched on sex, age and municipality of residence. Follow-up was censored at death, emigration or end of study (31 December 2019). The dataset includes comprehensive information based on several registries, and includes diagnoses, prescribed medications and socioeconomic factors both prior to inclusion and during follow-up.
During the study period, the number of cases of acute pancreatitis in Sweden has more than doubled from 1977 cases in 1990 to 4264 cases in 2019. The median age of first episode of acute pancreatitis has increased from 58 years (IQR 44-73 years) in 1990 to 64 years (IQR 49-76 years) in 2019. Cases with acute pancreatitis were generally less healthy compared with the pancreatitis-free individuals (Charlson Comorbidity Index of 0 in 59.2% and 71.4%, respectively).
SwePan will be used to determine the incidence of acute pancreatitis in Sweden over time and assess long-term all-cause and cause-specific mortality after an episode of acute pancreatitis. Some examples of additional planned studies are (1) assessment of long-term risk of diabetes and (2) risk of malignancy in adjacent organs following acute pancreatitis and (3) assessment of risk factors for development of acute pancreatitis including various drugs.
瑞典胰腺炎队列（SwePan）旨在研究急性胰腺炎发作后的长期结局。它还可用于研究急性胰腺炎发生的各种危险因素。
SwePan 是一个基于登记的全国性匹配队列。它包含了 1990 年至 2019 年期间瑞典所有的急性胰腺炎病例。该队列包括 95632 例急性胰腺炎患者和 952783 例胰腺炎对照者，按性别、年龄和居住地的市政当局匹配。随访截止于死亡、移民或研究结束（2019 年 12 月 31 日）。该数据集包含了基于多个登记处的综合信息，包括纳入前和随访期间的诊断、处方药物和社会经济因素。
在研究期间，瑞典急性胰腺炎的病例数增加了一倍以上，从 1990 年的 1977 例增加到 2019 年的 4264 例。首次急性胰腺炎发作的中位年龄从 1990 年的 58 岁（四分位距 44-73 岁）增加到 2019 年的 64 岁（四分位距 49-76 岁）。与胰腺炎对照组相比，急性胰腺炎患者的健康状况通常较差（Charlson 合并症指数为 0 的分别占 59.2%和 71.4%）。
SwePan 将用于确定瑞典急性胰腺炎的发病率随时间的变化，并评估急性胰腺炎发作后的全因和特定原因死亡率。计划开展的一些额外研究包括（1）评估长期糖尿病风险，（2）急性胰腺炎后邻近器官恶性肿瘤的风险，（3）评估急性胰腺炎发生的危险因素，包括各种药物。
